Hints and tips:
Related Special Reports
Novo Nordisk, Bill & Melinda Gates Foundation and Wellcome focus on interlinked issues
...“All it takes is one large company like Eli Lilly to do it and then more risk-averse companies follow suit,” he said....
...Soriot already earns more than bosses of larger European pharmaceutical companies....
...Curaleaf is the world’s largest cannabis company, with a market capitalisation of C$4.6bn, and its shares have risen 40 per cent in the past year....
...The British pharmaceutical company is preparing for a vote on its long-serving leader’s pay at the annual meeting on Thursday, including a rise that would take his package to a maximum of £18.7mn....
...The ImmunoGen deal came four decades after the company started working on the first generation of ADCs....
...Eli Lilly’s chief executive David Ricks attributed the drugmaker’s performance to “strong sales of Mounjaro and Zepbound”, and said the company was “rapidly expanding manufacturing capacity to make our incretin...
...The announcement comes after the pharmaceutical group requested in March that the European Union marketing authorisation for Vaxzevria be withdrawn, a request that was granted on Tuesday....
...Isomorphic Labs has partnerships with pharmaceutical companies Eli Lilly and Novartis....
...It comes as more companies look to help employees with mental health, offering access to therapy, or apps....
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
...The partnership strengthens Sanofi, one of the world’s largest vaccine makers by sales, in the post-pandemic Covid jab market, where pharmaceutical groups are increasingly focused on combined shots against...
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...Aim biotech companies complain of liquidity constraints, high regulatory costs and limited access to funding....
...It needs further deals to replenish its pharmaceuticals pipeline....
...No concessions of liability have been made,” the company said....
...“The company’s main biological asset are NHPs used for pre-clinical trials....
...After being approached by the Financial Times for comment, Amy Emerson, Lykos’ chief executive, said in a statement that the company “[looked] forward to the opportunity to discuss” its treatment application...
...But pharmaceutical companies can file several patents for single drugs at different times, delaying the entry of generic medicines....
...company’s biggest-selling drugs....
...The UK-based pharmaceutical group reported revenue of $12.7bn for the first quarter of 2024, an increase of 19 per cent, well ahead of consensus estimates of $11.9bn....
...Erik Haas, the company’s worldwide vice-president of litigation, said it was “the culmination of our consensual resolution strategy that we announced last October”....
...It is a similar milestone-based structure to many partnerships in the pharmaceutical industry....
...Last year, at the height of pricing negotiations, leaders from 16 of the world’s largest generic and biosimilar companies wrote asking for clarity on specific aspects of the deal....
...Any rumours that the company is at risk of defaulting are “flatly untrue”, he said....
International Edition